Editor’s note: This is a developing news story. Please check back soon for updates.
LKC Technologies, maker of the RetEval handheld electroretinography device, has been acquired by Ametek, according to a press release.
“Becoming part of Ametek is a powerful validation of what our customers and partners have already recognized — LKC is building something lasting,” Dina Dubey, CEO of LKC Technologies, said in the release. “We are joining a financially strong, publicly traded global organization that has been listed on the New York Stock Exchange for more than 95

ACOG announced its withdrawal as a liaison organization to the CDC’s Advisory Committee on Immunization Practices, or ACIP, due to concerns about recent changes to the committee.
According to the organization, there have been a number of developments which “undermine the committee’s scientific integrity and evidence-based approach to vaccine policy.”
“For decades, we have proudly participated in ACIP to ensure that vaccine recommendations are grounded in rigorous scientific evidence and protect the health of pregnant women, children and families,” ACOG President Steven J. Fleischman, MD, MBA,

MIAMI BEACH, Fla. — The cosmetic market’s boom now includes multiple neuromodulator options to treat a variety of aesthetic concerns, with more options expected within the next year, according to a speaker at South Beach Symposium.
In 2002, onabotulinumtoxinA (Botox Cosmetic, AbbVie) became the first neuromodulator approved for an aesthetic indication. Since then, the cosmetic field has seen rapid growth, according to Brian P. Hibler, MD, FAAD, a dermatologist at Schweiger Dermatology Group in New York.
“It’s 23 years after the first FDA approval of Botox Cosmetic and we’re seeing so much

DENVER — Researchers here presented what they said is the first evidence demonstrating that benefits paid through the Supplemental Nutrition Assistance Program, or SNAP, can improve a person’s adherence to HIV medication.
The findings are timely, coming as new federal legislation is about to make it harder for people to qualify for SNAP benefits, which many people with HIV rely on.
Treatment is essential for HIV prevention and control. Taken as prescribed, modern ART regimens can reduce a person’s HIV viral load to undetectable levels, preventing them from sexually transmitting the virus to

A new survey suggests that most Americans are familiar with statins, but most are not aware of nonstatin cholesterol-lowering therapies and other tools to combat heart disease.
The survey of 1,006 American adults, commissioned by The Ohio State University Wexner Medical Center and conducted in December, determined that 60% knew of statins, but 61% were not familiar with nonstatin lipid-lowering medications, 73% had never heard of lipoprotein(a), 67% had never heard of coronary artery calcium scoring and only 44% said they believe that statins are an effective and proven treatment for lowering

In 2024, the FDA granted 510(k) clearance to a hemodialysis machine capable of delivering online high-volume hemodiafiltration. Since then, companies have started phased introduction of the system into dialysis clinics across the country.
This regulatory and clinical milestone has renewed attention to a longstanding limitation of conventional hemodialysis: inadequate clearance of middle-molecular-weight uremic toxins, or middle molecules.

Middle molecules are traditionally classified as solutes ranging from 500 Da to 60,000 Da. These molecules are larger than urea and creatinine and, therefore,

Adults with differentiated thyroid cancer who are using a GLP-1 for the treatment of diabetes or obesity do not have increased risk for cancer recurrence or progression vs. those not using a GLP-1, researchers reported.
Laura Boucai, MD, MSc, clinical member at Memorial Sloan Kettering Cancer Center and associate professor of clinical medicine at Weill Cornell Medical College in New York, said some previously published epidemiological studies have found associations between the use of GLP-1s and new-onset thyroid cancer. However, Boucai noted those associations may be due to increased

The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, according to a press release.
On Jan. 20, the FDA granted approval for the Zepbound KwikPen, an injection pen equipped with four doses of once-weekly tirzepatide (Zepbound, Eli Lilly). On Feb. 23, Eli Lilly announced in a press release that the Zepbound KwikPen is available for patients, with the self-pay price starting at $299 per month for a 2.5 mg dose. Zepbound is available in doses of 2.5 mg,

A large language model delivered high sensitivity and specificity in analyzing electronic health records of patients for thrombolysis contraindications during stroke evaluations, according to a poster at the International Stroke Conference.
“In acute stroke, thrombolysis decisions are time-critical and hinge on quickly identifying contraindications buried in the EHR,” Bing Yu Chen, MD, neurology physician at the Cleveland Clinic, told Healio. “Manual chart review can be slow and variable, especially under time pressure, and missed contraindications can lead to devastating bleeding

WAIKOLOA, Hawaii — In this expert perspective from Hawaiian Eye 2026, Marguerite B. McDonald, MD, FACS, discusses the use of DefEYE’s Biovance 3L Ocular decellularized basement membrane for the treatment of neurotrophic keratitis.
“It works,” McDonald, of OCLI Vision, told Healio. “It’s comfortable. More and more of my peers are using it. I certainly use it as a first-line treatment for [neurotrophic keratitis] starting at stage one and above.”